Promise Bio

What Promise Bio does

Promise Bio is a Tel Aviv-based precision medicine company, founded in 2023-2024 as a spinout from the Weizmann Institute of Science, that has built a cloud-based AI platform for epiproteomic analysis of post-translational protein modifications (PTMs) in blood samples. The platform processes standard mass-spectrometry data — without requiring chemical enrichment — to predict patient treatment response, stratify patients, and discover biomarkers for immune-mediated and autoimmune diseases. Underlying capabilities include unbiased broad-range PTM landscape exploration, explainable AI algorithms tailored for clinical interpretation, and continuously evolving models that can revisit previously collected mass-spectrometry datasets to surface new insights.

The company serves two interlocking customer segments: pharmaceutical and biotech companies seeking biomarker discovery, patient selection, and clinical trial enrichment for novel therapeutics, and healthcare providers treating autoimmune diseases who need precision diagnostics to replace trial-and-error prescribing. The business model is anchored in enterprise field sales to major pharmaceutical companies (with Pfizer and AstraZeneca both seed investors), supplemented by licensing/collaborative revenue streams and a service-based Frontier Epiproteomic Innovation Grant that provides biotech participants with epiproteomic profiling and analysis. Marketing is concentrated in industry summits and direct partnership outreach rather than broad-channel distribution, reflecting a B2B enterprise go-to-market with high-touch deal economics.

Name

Promise Bio

Legal name

PromiseBio

Website

https://promise.bio

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

11–50 employees

Short description

Promise Bio is a Tel Aviv-based AI precision medicine company that analyzes blood-sample epiproteomics to predict treatment response, stratify patients, and discover biomarkers for autoimmune diseases, serving pharmaceutical and biotech partners developing novel therapeutics.

Ownership category

akta.pro rank

Product category

Precision Medicine / Epiproteomics Software

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Prepackaged Software (7372)

akta.pro primary industry

Biomarker Discovery & Validation (omics, assay feasibility, clinical validation) (HLAAAMAA)

akta.pro secondary industries

Predictive Biomarkers for Therapy Selection (response/non-response stratification) (HLAAAMAE), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

Keywords

• Epiproteomics analysis
• Precision medicine platform
• Autoimmune diagnostics
• Biomarker discovery
• AI drug development

Headquarters

HQ city

Tel Aviv

HQ country

Israel

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

1. Licensing Revenue: The company aims to create licensing revenue streams by providing its AI-based platform for epiproteomics analysis to pharmaceutical and biotech companies.
2. Collaborative Partnerships: Collaborative revenue streams with pharmaceutical companies for drug development support, biomarker discovery, patient selection, and clinical trial enrichment.
3. Frontier Epiproteomic Innovation Grant: R&D access initiative providing select biotech participants with comprehensive analysis and insights from mass-spectrometry data to aid drug development decisions. This represents a service-based revenue model for translational epiproteomic analysis.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels2 records

Core offering

Promise Bio offers a cloud-based AI platform that performs unbiased, broad-range epiproteomic analyses on standard mass-spectrometry data to predict patient treatment responses, stratify patients, and enable biomarker and target discovery for immune-mediated (autoimmune) diseases. The platform integrates chemical knowledge, statistics, and explainable AI to interpret Post-Translational Modifications (PTMs) without requiring chemical enrichment, and supports pharmaceutical and biotech partners across treatment selection, disease monitoring, biomarker discovery, patient selection, and clinical trial enrichment.

Product overview

Promise Bio offers a unified cloud-based AI platform for precision medicine in autoimmune diseases, centered on epiproteomic analysis of post-translational protein modifications. The platform integrates with standard mass-spectrometry data to provide treatment response predictions, patient stratification, biomarker discovery, and clinical trial enrichment. The portfolio includes the core Cloud-Based AI Platform as the primary offering, supplemented by the Frontier Epiproteomic Innovation Grant—an R&D access initiative enabling biotech partners to access epiproteomic profiling services.

Differentiator

Problem solved

Functional benefit

Products and services

• Cloud-Based AI Epiproteomics Platform A cloud-based AI platform that performs unbiased, broad-range epiproteomic analyses on standard mass-spectrometry data to predict patient treatment responses, enable patient stratification, and support biomarker discovery, patient selection, and clinical trial enrichment for pharmaceutical and biotech companies developing therapeutics for immune-mediated diseases.
• Frontier Epiproteomic Innovation Grant An R&D access initiative providing select biotech companies developing novel therapeutics with comprehensive epiproteomic analysis and insights derived from mass-spectrometry data to support their drug development decisions.

Quantifiable outcome

• Replacing trial-and-error prescribing which costs over $100 billion annually in the U.S.
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• Weizmann Institute of SciencecoreStrategic or Co-development PartnerPromise Bio's platform is built on foundational research from the Weizmann Institute of Science. Scientific co-founder Prof. Yifat Merbl is an Associate Professor at Weizmann, and her lab developed proprietary platform technologies that set the basis for Promise Bio's translational research capabilities.
• Biotech Companies (Innovation Grant Participants)coreStrategic or Co-development PartnerPromise Bio launched the Frontier Epiproteomic Innovation Grant program to support biotech companies developing novel therapeutics through epiproteomic profiling and analysis. Selected participants receive comprehensive analysis and insights from mass-spectrometry data.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Olink Holding: Olink offers proximity extension assay-based proteomics platforms widely adopted by pharma for biomarker discovery and translational research. Overlaps with Promise Bio in protein biomarker-based patient stratification and clinical trial enrichment workflows.
• Standard BioTools (formerly Fluidigm): Standard BioTools provides mass cytometry and analytical instruments used in proteomics and biomarker workflows for translational research. Provides complementary analytical infrastructure in the same biomarker discovery ecosystem that Promise Bio addresses via software/AI.
• Seer: Seer provides a commercial proteomics platform (Proteograph) for unbiased, large-scale protein and PTM analysis. Directly competes with Promise Bio in deep proteomics/epiproteomics-based biomarker discovery for pharma and clinical research customers.
• Nautilus Biotechnology: Nautilus is developing a single-molecule protein analysis platform aimed at comprehensive proteome and PTM characterization. Competes with Promise Bio in next-generation proteomics for biomarker and target discovery in pharma.
• SomaLogic: SomaLogic operates the SomaScan proteomics platform, serving pharma R&D and clinical research with high-throughput protein biomarker measurements. Comparable to Promise Bio in commercial proteomics-driven drug development and patient stratification use cases.

Emerging players

• C2i Genomics: C2i Genomics provides AI-based liquid biopsy and tumor analytics for pharma clinical trials and patient monitoring. Comparable in its AI biomarker and clinical-trial-enrichment positioning; CEO Ronel Veksler previously served as Senior Director of Product at C2i.
• Owkin: Owkin applies AI to patient-level biomedical data (multi-omics, pathology, clinical) for pharma biomarker and drug development partnerships. Comparable to Promise Bio in AI-driven biomarker and patient stratification use cases, particularly in immune-mediated and inflammatory disease.
• Aitia (formerly Intrexon Bioinformatics): Aitia uses AI/causal inference on multi-omics data to discover biomarkers and therapeutic targets for oncology and immuno-oncology. Overlaps with Promise Bio in AI-driven biomarker discovery for pharma, though focused on causal 'digital twin' biology.

Broad incumbents

• Recursion Pharmaceuticals: Recursion combines high-throughput biology with AI/ML to discover and develop therapeutics at scale. Comparable as a broad AI-for-drug-discovery platform that engages pharma for partnerships, though it operates a much larger pipeline and infrastructure.
• Insilico Medicine: Insilico Medicine is an AI-driven drug discovery company with end-to-end biology-to-molecule capabilities. Broader incumbent that overlaps with Promise Bio in pharma-facing AI biomarker and target discovery, though it owns a fully integrated drug pipeline.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/promise-bio

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Promise Bio